Anti-CD161 antibodies and methods of use thereof

WO2024229461A3PCT designated stage expired Publication Date: 2024-12-26NOVASENTA INC
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
PCT/US2024/028001
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-04
Filing Date
2024-05-06
Publication Date
2024-12-26

AI Technical Summary

Technical Problem

Current immunotherapies for cancer face challenges such as immunoresistance and variable effectiveness due to tumors' ability to evade immune surveillance, necessitating new therapies that can induce an immune response in immunosuppressive environments.

Method used

Development of anti-CD161 antibodies that specifically bind to CD161, inhibiting its interaction with CLEC2D, thereby enhancing immune cell activation and cytokine production, including IL-2, TNF-alpha, and IFN-gamma, to boost the immune response against cancer cells.

Benefits of technology

The anti-CD161 antibodies effectively increase cytokine production and enhance immune cell activation, overcoming immunoresistance and improving treatment outcomes for various cancers by promoting a robust immune response.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 000001
    Figure 000001
  • Figure 000002
    Figure 000002
  • Figure 000003
    Figure 000003
Patent Text Reader

Abstract

The present disclosure provides antibodies and antigen-binding portions thereof that bind CD161, bispecific antibodies and multispecific antibodies comprising the same, nucleic acids and vectors encoding the same, and methods of using the same to treat a subject in need thereof.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Methods and compositions for treating cancer by targeting the CLEC2d-KLRB1 pathway

    US20210363260A1

  • Monoclonal antibodies that bind human CD161 and uses thereof

    WO2021080682A1

  • Anti-CD161 antibodies and uses thereof

    WO2023028501A1